The MOU marks a significant milestone in advancing clinical research in Taiwan, extending its influence beyond TMU to benefit its three affiliated hospitals: Taipei Medical University Hospital (TMUH), Taipei Municipal Wanfang Hospital (WFH), and Taipei Medical University-Shuang Ho Hospital (SHH). Recognized as a Center of Excellence by Taiwan’s Ministry of Health and Welfare, TMU is dedicated to advancing new treatments and refining medical guidelines, with the goal of enhancing the health and well-being of the community.
As an expert in early-phase clinical trials, Avance Clinical brings deep experience in supporting biotech companies with streamlined and high-quality trial execution. Meanwhile, TMU and its affiliated hospitals are eager to further expand their involvement in conducing early-phase studies while Avance Clinical seeks to broaden its service offerings into late-phase studies, an area where TMU has extensive experience. This partnership aligns with the strategic goals of both organizations, fostering a synergy collaboration that strengthens research capabilities across all phases of drug development.
“Partnering with Taipei Medical University and its three affiliated hospitals presents a unique opportunity to expand our clinical trial capabilities in Asia”, said Yvonne Lungershausen, CEO at Avance Clinical. “This agreement not only strengthens our presence in Taiwan but also ensures seamless trial execution across multiple high-caliber medical institutions.”
Professor Chun-Che Shih, Executive Vice President of Taipei Medical University, also expressed enthusiasm about the partnership: “We are excited to collaborate with Avance Clinical to advance clinical research and bring new treatment opportunities to patients. This partnership enhances our medical centers’ ability to make a significant impact, strengthens our presence in global trials, and ultimately improves healthcare through innovation.”
About Taipei Medical University
With cutting-edge research facilities and a strong commitment to clinical excellence, Taipei Medical University (TMU) and its affiliated hospitals enhance global clinical trial capabilities. Established in 1960, TMU has expanded to include a university, seven affiliated institutions, and two campuses. It operates two medical centers and one quasi-medical center. In 2024, TMU was honored with Global View’s Best Teaching Award and recognized as the most reputable private university in Taiwan For more information, visit eng.tmu.edu.tw.
About Avance Clinical
Avance Clinical is a leading global CRO specializing in early to late-phase clinical trials for biotech companies. Headquartered in Australia, Avance Clinical delivers faster, more flexible, and high-quality clinical trial solutions with a strong focus on regulatory compliance and patient-centric research. With a global footprint spanning Australia, New Zealand, Asia, North America, and Europe, Avance Clinical offers comprehensive support from preclinical consulting to Phase I-III trials, ensuring biotech sponsors achieve efficient trial execution and regulatory success.
